scholarly journals Serum Antibody Responses after Intradermal Injection of Influenza Vaccine

2005 ◽  
Vol 2 (1) ◽  
pp. 35-38
Author(s):  
Maliheh Metanat ◽  
Masoud Salehi . ◽  
Batool Sharifi-Mood . ◽  
Mohammad-Reza Safai .
Keyword(s):  
Influenza Vaccine ◽  
Serum Antibody ◽  
Intradermal Injection ◽  
Antibody Responses

scholarly journals Serum Antibody Responses after Intradermal Injection of Influenza Vaccine*

2009 ◽  
Vol 6 (1) ◽  
pp. 41-44
Author(s):  
Maliheh Metanat ◽  
Masoud Salehi ◽  
Batool Sharifi-Mo ◽  
Mohammad-Reza Safai
Keyword(s):  
Influenza Vaccine ◽  
Serum Antibody ◽  
Intradermal Injection ◽  
Antibody Responses

scholarly journals Plasma cell and serum antibody responses to influenza vaccine in preterm and full-term infants

Vaccine ◽  
2017 ◽  
Vol 35 (38) ◽  
pp. 5163-5171 ◽  
Author(s):  
Carl T. D'Angio ◽  
Claire P. Wyman ◽  
Ravi S. Misra ◽  
Jessica L. Halliley ◽  
Hongyue Wang ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Plasma Cell ◽  
Serum Antibody ◽  
Full Term ◽  
Antibody Responses ◽  
Term Infants

scholarly journals Serum and Mucosal Immune Responses to an Inactivated Influenza Virus Vaccine Induced by Epidermal Powder Immunization

2001 ◽  
Vol 75 (17) ◽  
pp. 7956-7965 ◽  
Author(s):  
Dexiang Chen ◽  
Sangeeta B. Periwal ◽  
Katherine Larrivee ◽  
Cindy Zuleger ◽  
Cherie A. Erickson ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Influenza Vaccine ◽  
Virus Vaccine ◽  
Serum Antibody ◽  
Immunoglobulin A ◽  
Influenza Virus Vaccine ◽  
Antibody Responses ◽  
Promising Alternative ◽  
Cpg Dna ◽  
Epidermal Powder Immunization

ABSTRACT Both circulating and mucosal antibodies are considered important for protection against infection by influenza virus in humans and animals. However, current inactivated vaccines administered by intramuscular injection using a syringe and needle elicit primarily circulating antibodies. In this study, we report that epidermal powder immunization (EPI) via a unique powder delivery system elicits both serum and mucosal antibodies to an inactivated influenza virus vaccine. Serum antibody responses to influenza vaccine following EPI were enhanced by codelivery of cholera toxin (CT), a synthetic oligodeoxynucleotide containing immunostimulatory CpG motifs (CpG DNA), or the combination of these two adjuvants. In addition, secretory immunoglobulin A (sIgA) antibodies were detected in the saliva and mucosal lavages of the small intestine, trachea, and vaginal tract, although the titers were much lower than the IgG titers. The local origin of the sIgA antibodies was further shown by measuring antibodies released from cultured tracheal and small intestinal fragments and by detecting antigen-specific IgA-secreting cells in the lamina propria using ELISPOT assays. EPI with a single dose of influenza vaccine containing CT or CT and CpG DNA conferred complete protection against lethal challenges with an influenza virus isolated 30 years ago, whereas a prime and boost immunizations were required for protection in the absence of an adjuvant. The ability to elicit augmented circulating antibody and mucosal antibody responses makes EPI a promising alternative to needle injection for administering vaccines against influenza and other diseases.

scholarly journals Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections

Antibiotics ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 627
Author(s):  
Sławomir Letkiewicz ◽  
Marzanna Łusiak-Szelachowska ◽  
Ryszard Międzybrodzki ◽  
Maciej Żaczek ◽  
Beata Weber-Dąbrowska ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bacterial Infections ◽  
Phage Therapy ◽  
Serum Antibody ◽  
Multidrug Resistant ◽  
Antibody Responses ◽  
Urogenital Infections ◽  
Reliable Model ◽  
Tract Infections ◽  
Antibody Levels

Patients with chronic urinary and urogenital multidrug resistant bacterial infections received phage therapy (PT) using intravesical or intravesical and intravaginal phage administration. A single course of PT did not induce significant serum antibody responses against administered phage. Whilst the second cycle of PT caused a significant increase in antibody levels, they nevertheless remained quite low. These data combined with good therapy results achieved in some patients suggest that this mode of PT may be an efficient means of therapy for urogenital infections and a reliable model for a clinical trial of PT.

scholarly journals Induction of Mucosal Protection against Primary, Heterologous Simian Immunodeficiency Virus by a DNA Vaccine

2002 ◽  
Vol 76 (7) ◽  
pp. 3309-3317 ◽  
Author(s):  
Deborah Heydenburg Fuller ◽  
Premeela A. Rajakumar ◽  
Lawrence A. Wilson ◽  
Anita M. Trichel ◽  
James T. Fuller ◽  
...  
Keyword(s):  
Simian Immunodeficiency Virus ◽  
Dna Vaccine ◽  
Dna Sequences ◽  
Serum Antibody ◽  
Antibody Responses ◽  
Effective Vaccine ◽  
Lymphoid Tissues ◽  
Mucosal Protection ◽  
Mucosal Transmission ◽  
Immunodeficiency Virus

ABSTRACT An effective vaccine against human immunodeficiency virus (HIV) should protect against mucosal transmission of genetically divergent isolates. As a safe alternative to live attenuated vaccines, the immunogenicity and protective efficacy of a DNA vaccine containing simian immunodeficiency virus (SIV) strain 17E-Fr (SIV/17E-Fr) gag-pol-env was analyzed in rhesus macaques. Significant levels of cytotoxic T lymphocytes (CTL), but low to undetectable serum antibody responses, were observed following multiple immunizations. SIV-specific mucosal antibodies and CTL were also detected in rectal washes and gut-associated lymphoid tissues, respectively. Vaccinated and naive control monkeys were challenged intrarectally with SIV strain DeltaB670 (SIV/DeltaB670), a primary isolate whose env is 15% dissimilar to that of the vaccine strain. Four of seven vaccinees were protected from infection as determined by the inability to identify viral RNA or DNA sequences in the peripheral blood and the absence of anamnestic antibody responses postchallenge. This is the first report of mucosal protection against a primary pathogenic, heterologous isolate of SIV by using a commercially viable vaccine approach. These results support further development of a DNA vaccine for protection against HIV.

scholarly journals High-Affinity H7 Head and Stalk Domain–Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine

2015 ◽  
Vol 212 (8) ◽  
pp. 1270-1278 ◽  
Author(s):  
Jessica L. Halliley ◽  
Surender Khurana ◽  
Florian Krammer ◽  
Theresa Fitzgerald ◽  
Elizabeth M. Coyle ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Specific Antibody ◽  
Antibody Responses ◽  
Domain Specific ◽  
High Affinity ◽  
Live Attenuated Influenza Vaccine ◽  
Stalk Domain

scholarly journals Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure

2018 ◽  
Vol 9 ◽  
Author(s):  
Vipin Narang ◽  
Yanxia Lu ◽  
Crystal Tan ◽  
Xavier F. N. Camous ◽  
Shwe Zin Nyunt ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Community Dwelling ◽  
Antibody Responses

scholarly journals An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination

2021 ◽  
Vol 118 (45) ◽  
pp. e2110817118
Author(s):  
Dengning Xia ◽  
Rui Jin ◽  
Gaurav Byagathvalli ◽  
Huan Yu ◽  
Ling Ye ◽  
...  
Keyword(s):  
Immune Responses ◽  
Large Scale ◽  
Low Cost ◽  
Electrode Array ◽  
Dna Vaccination ◽  
Intradermal Injection ◽  
Antibody Responses ◽  
Transient Effects ◽  
Electric Pulses ◽  
High Electric Field Strength

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other pathogens with pandemic potential requires safe, protective, inexpensive, and easily accessible vaccines that can be developed and manufactured rapidly at a large scale. DNA vaccines can achieve these criteria, but induction of strong immune responses has often required bulky, expensive electroporation devices. Here, we report an ultra-low-cost (<1 USD), handheld (<50 g) electroporation system utilizing a microneedle electrode array (“ePatch”) for DNA vaccination against SARS-CoV-2. The low cost and small size are achieved by combining a thumb-operated piezoelectric pulser derived from a common household stove lighter that emits microsecond, bipolar, oscillatory electric pulses and a microneedle electrode array that targets delivery of high electric field strength pulses to the skin’s epidermis. Antibody responses against SARS-CoV-2 induced by this electroporation system in mice were strong and enabled at least 10-fold dose sparing compared to conventional intramuscular or intradermal injection of the DNA vaccine. Vaccination was well tolerated with mild, transient effects on the skin. This ePatch system is easily portable, without any battery or other power source supply, offering an attractive, inexpensive approach for rapid and accessible DNA vaccination to combat COVID-19, as well as other epidemics.

scholarly journals Antigenic assessment of the H3N2 component of the 2019-2020 Northern Hemisphere influenza vaccine

2020 ◽  
Author(s):  
Sigrid Gouma ◽  
Madison Weirick ◽  
Scott E. Hensley
Keyword(s):  
Influenza Vaccine ◽  
Northern Hemisphere ◽  
Vaccine Strain ◽  
Antibody Responses ◽  
Wild Type ◽  
H3n2 Vaccine

AbstractThe 2019-2020 Northern Hemisphere influenza vaccine includes antigens from 3c3.A H3N2 viruses; however, over half of circulating H3N2 viruses belong to subclade 3c2.A1b. Here, we analyzed antibody responses elicited by the egg-adapted 3c3.A H3N2 vaccine strain in ferrets and humans. We found that this vaccine strain elicits antibodies that have reduced reactivity to a wild-type 3c3.A strain and very limited reactivity to 3c2.A strains, including the currently circulating 3c2.A1b strain.

Sign in / Sign up

Export Citation Format

Share Document